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Abstract
Background: Prognosis of patients with loco-regional skin metastases has not been analyzed in detail and the presence or
absence of concurrent lymph node metastasis represents the only established prognostic factor thus far. Most studies were
limited to patients already presenting with skin lesions at the time of initial diagnosis. We aimed to analyze the impact of a
broad penal of prognostic factors in patients with skin metastases at the time of first metastatic spread, including patients
with synchronous lesions already present at the time of initial diagnosis, stage I/II patients with loco-regional recurrence and
patients initially presenting with skin metastasis but unknown primary melanoma.
Patients and Methods: We investigated disease-specific survival of 380 patients treated at our department between 1996
and 2010 using Kaplan Meier survival probabilities and Cox-proportional hazard analysis.
Results: Five-year survival probability was 60.1% for patients with skin metastases only and 36.3% for those with
synchronous nodal metastases. The number of involved nodes and a tumor thickness of at least 3 mm had independent
negative impact on prognosis. A strong relationship was identified between the risk of death and the number of involved
nodes. Neither ulceration nor the timing of the first occurrence of metastases as either in stage I/II patients, at the time of
excision of the primary melanoma or initially in patients with unknown primary tumor, had additional effects on survival.
Conclusion: Lymph node involvement was confirmed as the most important prognostic factor for melanoma patients with
loco-regional skin metastasis including those with unknown primary tumor and stage I/II patients with skin recurrence.
Consideration of the tumor thickness and of the number of involved lymph nodes instead of the exclusive differentiation
into presence vs. absence of nodal disease may allow a more accurate prediction of prognosis for patients with satellite or
in-transit metastases.
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Introduction
The prognosis of melanoma patients with loco-regional
metastasis varies widely with 5-year survival rates ranging between
39% and 70% [1,2]. The most comprehensive investigation of
prognostic factors of melanoma patients with loco-regional
metastasis was conducted by the American Joint Committee on
Cancer (AJCC) who released the 7th edition of the classification
recommendation in 2009 [1]. The recommendation was based on
the multivariable analysis of more than 2900 patients with lymph
node metastasis and included the number of tumor-bearing nodes,
the tumor burden (microscopic vs. macroscopic) and ulceration of
the primary melanoma to assign patients to the different
prognostic sub-stages IIIA-C.
In contrast, prognosis of patients with loco-regional skin
metastases has not been analyzed in detail and the concurrent
presence or absence of lymph node metastasis represents the only
established prognostic factor thus far.
Patients with skin metastases but without lymph node involve-
ment were aligned to a distinct N category N2c (sub-stage IIIB)
based on a survival analysis of 399 melanoma patients [1]. Patients
with combined lymph node and skin metastases showed a worse
prognosis and were defined as N3 and therefore classified as sub-
stage IIIC, based on a similar prognosis compared to patients with
4 or more involved lymph nodes but no skin lesions. A detailed
analysis of prognostic markers in this patient cohort was not
published thus far. Other previous analyses were restricted to
patients receiving limb perfusion [3,4] to those with recurrences
[5,6] or were only performed in small cohorts of patients [7]. The
limited knowledge about prognosis of patients with skin metastases
hampers not only patient counseling but also led to the exclusion
of these patients in many clinical trials particularly in the adjuvant
setting [8–10].
Aim of this study was to identify prognostic factors in melanoma
patients with satellite or in-transit metastasis at the time of stage III
diagnosis in addition to the presence or absence of concurrent
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lymph node involvement to allow a more accurate prediction of
prognosis.
Methods
Ethics statement
All had given their written informed consent to have clinical
data recorded by the Central Malignant Melanoma Registry
(CMMR) registry. The institutional ethics committee Tu¨bingen
approved the study (ethic vote 711/2012R).
Patients
Patients with skin metastases treated between 1996 and 2010 at
the University Department of Dermatology in Tu¨bingen,
Germany, were identified in the Central Malignant Melanoma
Registry (CMMR) database which prospectively records patients
from more than 60 dermatological centers in Germany. The aims
and methods of data collection by the CMMR have previously
been reported in detail [11]. Only patients with loco regional skin
metastases or a combination of loco regional skin and lymph node
metastasis at the time point of first metastatic spread were included
into this analysis. Patients with prior loco-regional lymph-node
metastasis, or patients with concurrent or prior distant metastasis
were excluded. In this study, a skin metastasis was defined to be
localized either dermal or subcutaneously in the anatomical region
between the primary melanoma and the next proximal lymph
node basin (groin, axilla or cervical region). Patients with satellite-
and/or in-transit metastases were eligible, while those with isolated
true local recurrences resulting from an incompletely excised
primary tumor were excluded. Patients with unknown primary
melanoma were eligible if skin lesions were confined to one
anatomical region (e.g. one extremity) but were excluded, if there
was evidence of metastatic disease in more than one region with a
main lymph node basin in between (e.g. trunk and one extremity).
380 patients were finally included after individual file review.
Data obtained for each patient included gender, age at stage III
diagnosis (,60 vs. 60–69 vs. $70 years), situation at stage III
diagnosis (immediately metastasized melanoma vs. loco-regionally
relapsed melanoma vs. melanoma with unknown primary tumor
[MUP]), presence and number of synchronous lymph node
metastases (0 vs. 1 vs. 2–3 vs. 4 or more), date of the last follow-
up, and the date and cause of death, if applicable. The following
characteristics of the primary tumor were analyzed: body site
(axial vs. extremities), Breslow’s tumor thickness (,3 mm vs.
$3 mm), Clark’s level of invasion (I–III vs. IV vs. V), ulceration
(yes vs. no), and subtype (superficial spreading melanoma vs.
nodular melanoma vs. lentigo maligna melanoma vs. acral
lentiginous melanoma).
Statistical analysis
Follow-up time was defined from the date of diagnosis of the
first skin metastasis to the date of last follow-up or death. Estimates
of cumulative survival probabilities according to Kaplan-Meier
were described together with 95% confidence intervals (CIs) and
compared using two-sided log-rank test statistics. Median survival
times (MST) are presented. For the analysis of disease-specific
survival, patients who were alive at the last follow-up or died
without evidence of metastatic melanoma were considered to be
censored cases, while patients who had died due to melanoma
were considered an ‘‘event’’.
Multivariable Cox proportional hazard models were used to
determine independent prognostic factors. Categorized variables
were dummy coded to adhere to the linearity assumption of
multivariable regression analysis. All characteristics described
above were considered in the Cox regression models. Missing
values were assessed independently as a separate group to allow
the inclusion of patients with MUP. Forward and backward
stepwise procedures of the multivariable modeling process were
conducted. Results of the Cox models were described by means of
hazard ratios together with 95% CIs, p-values were based on the
Wald test.
Confounding was assessed by checking the effect of each
remaining non-significant variable, which was not in a model, on
factors in the model. If changes to the regression coefficient of a
factor in the model of 5% or more occurred, then the respective
variable was considered a confounder and the model was adjusted
for it. Throughout the analysis, p values less than 0.05 were
considered as statistically significant. All statistical analyses were
carried out using the SPSS Version 19 (IBM SPSS, Chicago,
Illinois, USA).
Results
Description of sample
Patient characteristics are shown in Table 1. A total of 380
melanoma patients (49% male) were included in the survival
analysis at the time of initial stage III diagnosis. The median age
was 66 years (inter quartile range [IQR] 55–73 years). The
median follow-up time for patients who died was 25 months
(IQR: 14–44) and 56 months (IQR: 26–102) for patients who were
alive at the last date of observation. The median survival time
according to Kaplan Meier (MST) was 74 months. Cumulative
survival rates were 92.5% (1 year), 77.7% (2-years), 54.6% (5-
years) and 42.1% (10-years). Overall, 50.5% of patients developed
the first loco-regional metastasis after the initial excision of the
primary melanoma in contrast to 34.5% who already presented
with metastases at the initial diagnosis and 15.0% who had an
unknown primary tumor.
Survival analysis of patients with in-transit/satellite
metastases
Five-year survival probability was 60.1% for patients with skin
metastases only and 36.3% for those with synchronous nodal
metastases (MST 35 months vs. 114 months, log rank p,0.001;
Fig. 1A), the number of involved lymph nodes (MST 13, 27 or 46,
114 months for respectively, four or more, two to three, one vs.
none involved node, p,0.001: Fig. 1B) and a tumor thickness of
3 mm or more (MST 42 months vs. 123 months, p,0.001;
Fig. 1C) were the characteristics with the most impact on survival.
Five-year survival rates are presented for all 380 patients with in-
transit/satellite metastases in Table 1. Multivariable Cox models
identified a strong and consistent correlation with the number of
involved lymph nodes (Table 2). The hazard ratios for melanoma-
specific death were 2.0 for one, 2.3 for two or three and 3.7 for
four or more nodal metastases and 1.7 for patients with primary
melanomas with a tumor thickness of at least 3 mm (Table 2). If
the number of nodes is neglected in patients with loco-regional
skin metastases like in the current AJCC stage III classification
algorithm, which only differentiates between presence vs. absence
of nodal disease the hazard ratio in case of additional metastastic
spread to the lymph nodes is 2.2. Bivariate analysis also showed
associations between ulceration, Clark’s level, or the histopatho-
logical subtype and survival, but these characteristics were no
longer found to be statistically significant in the multivariable
analysis. No association was found between gender, age or the
time of stage III diagnosis in the course of disease and survival in
either bi- or multivariable analysis.
Survival of Melanoma Patients with Skin Metastases
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Discussion
The current study has identified tumor thickness as an
independent prognostic factor for melanoma patients with satellite
or in-transit metastasis at the time point of first metastatic spread.
Furthermore, the already established prognostic impact of the
presence or absence of concurrent lymph node involvement was
confirmed. To the best of our knowledge, this analysis of 380
patients represents the largest cohort of stage III patients with skin
metastases which was analyzed using multivariable survival
analysis thus far. The novelty of our study in contrast to others
was to include stage I/II patients at the time of the first loco-
regional recurrence as well as patients with melanoma of unknown
primary tumor whose diagnosis was established by histopathologic
examination of skin metastases. Both subgroups generally com-
Table 1. Patient characteristics and survival analysis according to Kaplan-Meier.
Factor n % % Dead 5 Years survival rate [95%-CI*] (%) p **
Gender
Male 185 48.7 44.3 51.0 [42.8; 59.2] 0.225
Female 195 51.3 41 57.9 [50.1; 65.7]
Age
#60 years 132 34.7 48.5 52.5 [43.1; 61.9] 0.834
61–70years 119 31.3 42.9 58.0 [48.0; 68.0]
.70 years 129 33.9 36.4 52.2 [41.2; 63.2]
Body site of primary
Axial 147 45.5 46.9 52.8 [43.8; 61.8] 0.322
Extremities 176 54.5 41.5 56.1 [47.8; 64.3]
Missing data/unknown primary 0/57
Ulceration of the primary
Not ulcerated 196 59.3 39.1 61 [52.9; 69.0] 0.013
Ulcerated 135 40.7 48.1 49.1 [39.3; 58.9]
Missing data/unknown primary 19/57
Histological subtype of primary
SSM 121 44.2 39.7 62.2 [52.8; 71.6] 0.013
Nodular 88 32.1 50 50.7 [38.7; 62.6]
LMM 27 9.8 22.2 73.6 [55.4; 91.8]
ALM 38 13.9 57.9 33.7 [16.2; 51.1]
Missing data/unknown primary 49/57
Clark’s level of invasion
Level I–III 35 13.7 51.4 52.4 [35.3; 69.4] 0.034
Level IV 176 68.8 36.9 64.8 [56.8; 72.8]
Level V 45 17.6 53.3 34.9 [18.6; 51.2]
Data Missing/unknown primary 67/57
Breslow’s tumor thickness of primary
,3 mm 161 52.6 36.6 63.3 [55.1; 71.5] ,0.001
$3 mm 145 47.4 51.7 45.4 [36.0; 55.8]
Missing data/unknown primary 17/57
First occurrence of metastasis
Initially in patients with known primary 131 34.5 43.5 57.2 [47.6; 68.8] 0.879
During surveillance of stage I/II patients 192 50.5 44.3 52.9 [44.9; 60.9]
Initially in patients with unknown primary 57 15.0 35.1 54.7 [38.8; 70.5]
Number of involved nodes
0 293 77.1 36.5 60.1 [53.6; 66.6] ,0.001
1 39 10.3 61.5 39.9 [22.7; 57.1]
2–3 31 8.2 64.5 34.9 [16.5; 53.3]
$4 15 4.0 73.3 24.4 [0.7; 48.1]
Missing data 2
*95%-CI = 95% confidence interval; **p-values are results of log rank tests excluding cases with missing values; log rank test excluding cases without lymph node
metastasis and those with missing values.
doi:10.1371/journal.pone.0063137.t001
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prise the majority of stage III melanoma patients with skin
metastasis but were only included in limited number of prognostic
studies thus far [6,12]. In our cohort only 34.5% were patients
with synchronous primary melanoma and loco-regional skin
metastases like analyzed by Balch et al [1], while 50.5% were
recurrent stage I/II patients and 15% had MUP. The inclusion of
recurrent stage I/II patients allowed us to investigate, whether the
interval between primary melanoma and appearance of metastases
is a prognostic factor, a question that is still controversially
discussed [12–15]. While we were able to demonstrate an impact
on survival according to the interval between primary diagnosis
and appearance of distant metastases for stage IV patients [16], we
could not observe any difference according to the timing of the
first occurrence of metastases as either in stage I/II patients during
surveillance, at the time of excision of the primary melanoma or
initially in patients with MUP here for stage III patients.
MUP is still an unexplained phenomena. One hypothesis is the
regression of the primary melanoma mediated by an effective
immune response [17]. Lee et al [18] and Prens et al [19] both
demonstrated a clear survival advantage of patients with MUP
after therapeutic lymphadenectomy compared to patients with
known primary tumor and explained this observation with a
strong endogenous immune response directed against melanoma
resulting in both, regression of the primary tumor and a better
outcome. Survival was similar of patients with known and
unknown primary melanoma in our study and therefore not
suggestive for a clinically relevant immune privilege in MUP.
The results of our survival analysis are very similar to that
presented in the work of Balch et al, who reported 5-year survival
rates of 69% for N2c patients and 46% for patients with combined
skin and lymph node metastases (N3). The corresponding 10-years
survival rates were 52% and 33%, respectively [1]. Survival in our
study was slightly worse (5-year survival probability: 60.1%) but
almost identical if our analysis was restricted to patients with skin
metastasis already existing at the time of initial melanoma
diagnosis (5-year survival probability: 69.8%). For patients with
combined nodal and skin lesions Balch and co-workers found 5-
year survival rates of 46% in contrast to 36% observed here [1].
The discrepancy might reflect differences regarding the average
number of involved lymph nodes between both patient cohorts.
In the present study, concurrent lymph node involvement was
confirmed as the most important independent prognostic factor for
stage III patients with skin metastases. As already considered in the
AJCC classification, patients with combined skin and lymph node
involvement have a worse prognosis and are classified as stage IIIC
compared to those who present exclusively with skin lesions (stage
IIIB) [20]. The relative risk to die from melanoma for patients with
skin metastasis was 2.2-fold increased in case of concurrent lymph
node involvement. We further analyzed if the number of nodes, a
characteristic that is considered in the AJCC classification only for
patients with metastases confined to the lymph nodes is likewise
relevant for those patients with concurrent skin metastasis.
Although in our study the number of patients with combined skin
and lymph node metastasis was low (n= 87), we could still
demonstrate a strong impact of the number of metastatic nodes.
The relative risk to die from melanoma was increased according to
our multivariable analysis showing a consistent relationship
between the risk of melanoma-related death and the number of
involved lymph nodes. Consideration of the number of involved
lymph nodes instead of the exclusive differentiation into presence
vs. absence of nodal disease may therefore allow a more accurate
prediction of prognosis for patients with satellite or in-transit
metastases.
The second characteristic with independent unfavorable impact
on survival was a large tumor thickness of the primary melanoma.
This is in accordance with a study of Soong and co-workers who
included 236 patients with local skin recurrences and found
increasing tumor thickness and an axial localization of the primary
melanoma to be predictive of poor survival. Patients with skin
Figure 1. Overall survival of patients with loco-regional skin
metastases at the initial diagnosis of metastatic spread.
Cumulative survival probabilities are stratified by the presence or
absence of additional lymph node metastases (A), the number of
additional lymph node metastases (B), or the thickness of the primary
melanoma (C) estimated using Kaplan Meier survival analysis. Censored
events are indicated by vertical lines.
doi:10.1371/journal.pone.0063137.g001
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metastases already present at the time of initial melanoma
diagnosis and those with synchronously occurring lymph node
and skin metastases were excluded from this analysis [6].
Messeguer et al described 36 stage I/II patients who recurred
with loco-regional skin metastases. Survival after recurrence was
inversely influenced by a high mitotic activity and a large tumor
thickness [7]. Nevertheless, it was an unexpected finding that the
thickness of the primary melanoma is superior in predicting
prognosis for stage III patients with skin metastasis compared to
ulceration, which is associated with survival but does not add an
independent predictive impact on prognosis according to our
multivariate analysis. The opposite was described for patients with
metastases confined to the lymph nodes [2]. Balch and co-workers
separately analyzed patients with microscopic lymph node
metastases and those with macroscopic disease. In patients with
micro-metastasis both ulceration and tumor thickness had a
similar impact, while for patients with macro-metastasis tumor
thickness lost its independent prognostic role in multivariable
analysis [2].
Conclusion
In addition to lymph node involvement, which was confirmed as
the most important prognostic factor, the thickness of the primary
tumor was identified to independently contribute to prognosis of
melanoma patients with loco-regional skin metastases at the time
of the initial metastatic spread. No differences in survival were
observed between patients with synchronous skin metastasis
already present at the time of the excision of the primary tumor,
compared to stage I/II patients with skin recurrence or patients
with skin metastasis but unknown primary melanoma. Taking the
number of involved lymph nodes into account, as already
implemented in the AJCC stage III classification for patients with
nodal disease, may allow a more accurate prediction of prognosis
for patients with satellite or in-transit metastases.
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